Bachem stock gained 1.1 percent on October 2

Published on 10/04/2026 at 20:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bachem stock was last at CHF 79.60 on SIX on October 2, 2026, after a 1.1 percent session gain. H1 sales reached CHF 326.4 million and guidance targets 35 to 40 percent growth.

Fotorealistische Peptid-Produktionsanlage mit Alpenpanorama im Hintergrund — Bachem Holding AG (CH0012530207) betreibt moderne Peptid-Produktionsanlagen mit Bioreaktoren vor Schweizer Alpenpanorama, Illustration mit AI erstellt.

Bachem stock (ISIN CH1176493729) was last at CHF 79.60 on SIX on October 2, 2026, at 4:28 p.m. CEST, up 1.1 percent in the session. The latest half-year update showed sales of CHF 326.4 million in H1 2026, up 4 percent from H1 2025, according to Yahoo Finance on July 30, 2026.

H1 sales rose despite a high base

The comparison with H1 2025 is important because Bachem described that period as unusually strong. Sales still increased 4 percent in Swiss francs and 7.3 percent in local currencies, while EBIT reached CHF 82.8 million, according to Yahoo Finance.

The margin picture was more demanding. H1 EBITDA margin stood at 25.4 percent, with investment and operating costs weighing on profitability while the company prepared for additional capacity.

Capacity spending shapes the outlook

Bachem guided for 2026 sales growth of 35 to 40 percent in local currencies, revised from an earlier range of 35 to 45 percent, according to Yahoo Finance. The company also set 2026 capital expenditure guidance at CHF 350 million to CHF 400 million and retained an EBITDA margin outlook in the low 30 percent range.

The investment case therefore rests on execution as much as demand. Bachem plans more than CHF 500 million of investment at Sisslerfeld and expects commercial production there in 2030, while the Building K ramp-up is intended to support second-half sales, according to Yahoo Finance.

Consensus target sits above market price

The analyst picture remains constructive but dispersed. Investing.com lists a consensus Buy rating from 10 analysts, an average 12-month target of CHF 84.30, a high of CHF 110 and a low of CHF 50 as of September 25, 2026, in its Investing.com consensus overview. The average target lies 5.90 percent above the CHF 79.60 market price.

Stock remains below yearly high

Bachem stock was last at CHF 79.60 on SIX on October 2, 2026, placing it 5.35 percent below the 52-week high of CHF 84.10 reported for the same Swiss listing on October 1, 2026.